{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:46:53Z","timestamp":1792176413955,"version":"4.4.0"},"reference-count":271,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"DOI":"10.1038\/s41573-026-01548-7","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:02:15Z","timestamp":1792162935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Translating base editors: a decade of progress from the bench to the clinic"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8608-4855","authenticated-orcid":false,"given":"Nicole M.","family":"Gaudelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5043-0998","authenticated-orcid":false,"given":"Alexis C.","family":"Komor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"1548_CR1","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA\u2013guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821 (2012).","journal-title":"Science"},{"key":"1548_CR2","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00471","volume":"2","author":"M Jinek","year":"2013","unstructured":"Jinek, M. et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013).","journal-title":"eLife"},{"key":"1548_CR3","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"1548_CR4","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"1548_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nbt.2507","volume":"31","author":"SW Cho","year":"2013","unstructured":"Cho, S. W., Kim, S., Kim, J. M. & Kim, J.-S. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat. Biotechnol. 31, 230\u2013232 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","volume":"157","author":"PD Hsu","year":"2014","unstructured":"Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR\u2013Cas9 for genome engineering. Cell 157, 1262\u20131278 (2014).","journal-title":"Cell"},{"key":"1548_CR7","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229\u2013236 (2020).","journal-title":"Nature"},{"key":"1548_CR8","doi-asserted-by":"crossref","first-page":"1258096","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR\u2013Cas9. Science 346, 1258096 (2014).","journal-title":"Science"},{"key":"1548_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DBT Cox","year":"2015","unstructured":"Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121\u2013131 (2015).","journal-title":"Nat. Med."},{"key":"1548_CR10","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","volume":"37","author":"C Xue","year":"2021","unstructured":"Xue, C. & Greene, E. C. DNA repair pathway choices in CRISPR\u2013Cas9-mediated genome editing. Trends Genet. 37, 639\u2013656 (2021).","journal-title":"Trends Genet."},{"key":"1548_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/s41588-018-0174-0","volume":"50","author":"CD Richardson","year":"2018","unstructured":"Richardson, C. D. et al. CRISPR\u2013Cas9 genome editing in human cells occurs via the Fanconi anemia pathway. Nat. Genet. 50, 1132\u20131139 (2018).","journal-title":"Nat. Genet."},{"key":"1548_CR12","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1073\/pnas.91.13.6064","volume":"91","author":"P Rouet","year":"1994","unstructured":"Rouet, P., Smih, F. & Jasin, M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc. Natl Acad. Sci. USA 91, 6064\u20136068 (1994).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1548_CR13","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1038\/s41556-019-0425-z","volume":"21","author":"CD Yeh","year":"2019","unstructured":"Yeh, C. D., Richardson, C. D. & Corn, J. E. Advances in genome editing through control of DNA repair pathways. Nat. Cell Biol. 21, 1468\u20131478 (2019).","journal-title":"Nat. Cell Biol."},{"key":"1548_CR14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.molcel.2012.07.029","volume":"47","author":"JR Chapman","year":"2012","unstructured":"Chapman, J. R., Taylor, M. R. G. & Boulton, S. J. Playing the end game: DNA double-strand break repair pathway choice. Mol. Cell 47, 497\u2013510 (2012).","journal-title":"Mol. Cell"},{"key":"1548_CR15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.omtm.2023.06.003","volume":"30","author":"SR Dorset","year":"2023","unstructured":"Dorset, S. R. & Bak, R. O. The p53 challenge of hematopoietic stem cell gene editing. Mol. Ther. Methods Clin. Dev. 30, 83\u201389 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1548_CR16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","volume":"24","author":"G Schiroli","year":"2019","unstructured":"Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell 24, 551\u2013565 (2019).","journal-title":"Cell Stem Cell"},{"key":"1548_CR17","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med. 24, 927\u2013930 (2018).","journal-title":"Nat. Med."},{"key":"1548_CR18","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements. Nat. Biotechnol. 36, 765\u2013771 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR19","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","volume":"28","author":"G Turchiano","year":"2021","unstructured":"Turchiano, G. et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell 28, 1136\u20131147 (2021).","journal-title":"Cell Stem Cell"},{"key":"1548_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12028-5","volume":"10","author":"R Tuladhar","year":"2019","unstructured":"Tuladhar, R. et al. CRISPR\u2013Cas9-based mutagenesis frequently provokes on-target mRNA misregulation. Nat. Commun. 10, 4056 (2019).","journal-title":"Nat. Commun."},{"key":"1548_CR21","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","volume":"53","author":"ML Leibowitz","year":"2021","unstructured":"Leibowitz, M. L. et al. Chromothripsis as an on-target consequence of CRISPR\u2013Cas9 genome editing. Nat. Genet. 53, 895\u2013905 (2021).","journal-title":"Nat. Genet."},{"key":"1548_CR22","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1093\/stcltm\/szac064","volume":"11","author":"M Amendola","year":"2022","unstructured":"Amendola, M., Brusson, M. & Miccio, A. CRISPRthripsis: the risk of CRISPR\/Cas9-induced chromothripsis in gene therapy. Stem Cell Transl. Med. 11, 1003\u20131009 (2022).","journal-title":"Stem Cell Transl. Med."},{"key":"1548_CR23","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1093\/plcell\/koad209","volume":"35","author":"A Samach","year":"2023","unstructured":"Samach, A. et al. CRISPR\/Cas9-induced DNA breaks trigger crossover, chromosomal loss, and chromothripsis-like rearrangements. Plant Cell 35, 3957\u20133972 (2023).","journal-title":"Plant Cell"},{"key":"1548_CR24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016). This describes the initial development of cytosine base editing.","journal-title":"Nature"},{"key":"1548_CR25","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A\u2022T to G\u2022C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017). This describes the initial development of adenine base editing.","journal-title":"Nature"},{"key":"1548_CR26","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149\u2013157 (2019).","journal-title":"Nature"},{"key":"1548_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41576-018-0059-1","volume":"19","author":"HA Rees","year":"2018","unstructured":"Rees, H. A. & Liu, D. R. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat. Rev. Genet. 19, 770\u2013788 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"1548_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-020-0084-6","volume":"19","author":"EM Porto","year":"2020","unstructured":"Porto, E. M., Komor, A. C., Slaymaker, I. M. & Yeo, G. W. Base editing: advances and therapeutic opportunities. Nat. Rev. Drug Discov. 19, 839\u2013859 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1548_CR29","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824\u2013844 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s43586-026-00478-3","volume":"6","author":"SJ Mawson","year":"2026","unstructured":"Mawson, S. J., Dunne-Dombrink, K. A., Pollak, B. R. & Komor, A. C. Precision genome editing with DNA base editors. Nat. Rev. Methods Primers 6, 23 (2026).","journal-title":"Nat. Rev. Methods Primers"},{"key":"1548_CR31","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/s41589-022-01077-5","volume":"18","author":"DY Kim","year":"2022","unstructured":"Kim, D. Y. et al. Hypercompact adenine base editors based on a Cas12f variant guided by engineered RNA. Nat. Chem. Biol. 18, 1005\u20131013 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"1548_CR32","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-018-0011-0","volume":"37","author":"BP Kleinstiver","year":"2019","unstructured":"Kleinstiver, B. P. et al. Engineered CRISPR\u2013Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing. Nat. Biotechnol. 37, 276\u2013282 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR33","doi-asserted-by":"crossref","first-page":"107723","DOI":"10.1016\/j.celrep.2020.107723","volume":"31","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Cas12a base editors induce efficient and specific editing with low DNA damage response. Cell Rep. 31, 107723 (2020).","journal-title":"Cell Rep."},{"key":"1548_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nbt.4102","volume":"36","author":"X Li","year":"2018","unstructured":"Li, X. et al. Base editing with a Cpf1-cytidine deaminase fusion. Nat. Biotechnol. 36, 324\u2013327 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR35","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.cell.2022.03.039","volume":"185","author":"S-I Cho","year":"2022","unstructured":"Cho, S.-I. et al. Targeted A-to-G base editing in human mitochondrial DNA with programmable deaminases. Cell 185, 1764\u20131776 (2022).","journal-title":"Cell"},{"key":"1548_CR36","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41587-025-02685-x","volume":"44","author":"L Chen","year":"2026","unstructured":"Chen, L. et al. Efficient mitochondrial A-to-G base editors for the generation of mitochondrial disease models. Nat. Biotechnol. 44, 418\u2013429 (2026).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR37","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41587-022-01486-w","volume":"41","author":"S Lee","year":"2023","unstructured":"Lee, S., Lee, H., Baek, G. & Kim, J.-S. Precision mitochondrial DNA editing with high-fidelity DddA-derived base editors. Nat. Biotechnol. 41, 378\u2013386 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41586-020-2477-4","volume":"583","author":"BY Mok","year":"2020","unstructured":"Mok, B. Y. et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature 583, 631\u2013637 (2020).","journal-title":"Nature"},{"key":"1548_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45100-w","volume":"15","author":"F Fauser","year":"2024","unstructured":"Fauser, F. et al. Compact zinc finger architecture utilizing toxin-derived cytidine deaminases for highly efficient base editing in human cells. Nat. Commun. 15, 1181 (2024).","journal-title":"Nat. Commun."},{"key":"1548_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-27962-0","volume":"13","author":"K Lim","year":"2022","unstructured":"Lim, K., Cho, S.-I. & Kim, J.-S. Nuclear and mitochondrial DNA editing in human cells with zinc finger deaminases. Nat. Commun. 13, 366 (2022).","journal-title":"Nat. Commun."},{"key":"1548_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34784-7","volume":"13","author":"JCW Willis","year":"2022","unstructured":"Willis, J. C. W., Silva-Pinheiro, P., Widdup, L., Minczuk, M. & Liu, D. R. Compact zinc finger base editors that edit mitochondrial or nuclear DNA in vitro and in vivo. Nat. Commun. 13, 7204 (2022).","journal-title":"Nat. Commun."},{"key":"1548_CR42","doi-asserted-by":"publisher","first-page":"13330","DOI":"10.1038\/ncomms13330","volume":"7","author":"L Yang","year":"2016","unstructured":"Yang, L. et al. Engineering and optimising deaminase fusions for genome editing. Nat. Commun. 7, 13330 (2016).","journal-title":"Nat. Commun."},{"key":"1548_CR43","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41586-022-05114-0","volume":"609","author":"M Pacesa","year":"2022","unstructured":"Pacesa, M. et al. R-loop formation and conformational activation mechanisms of Cas9. Nature 609, 191\u2013196 (2022).","journal-title":"Nature"},{"key":"1548_CR44","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1126\/science.aad8282","volume":"351","author":"F Jiang","year":"2016","unstructured":"Jiang, F. et al. Structures of a CRISPR\u2013Cas9 R-loop complex primed for DNA cleavage. Science 351, 867\u2013871 (2016).","journal-title":"Science"},{"key":"1548_CR45","doi-asserted-by":"crossref","first-page":"1247997","DOI":"10.1126\/science.1247997","volume":"343","author":"M Jinek","year":"2014","unstructured":"Jinek, M. et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 343, 1247997 (2014).","journal-title":"Science"},{"key":"1548_CR46","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1126\/science.abb1390","volume":"369","author":"A Lapinaite","year":"2020","unstructured":"Lapinaite, A. et al. DNA capture by a CRISPR\u2013Cas9-guided adenine base editor. Science 369, 566\u2013571 (2020). This describes the first structural determination of a base editor.","journal-title":"Science"},{"key":"1548_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59948-z","volume":"16","author":"S Gu","year":"2025","unstructured":"Gu, S. et al. Elucidating the genetic mechanisms governing cytosine base editing outcomes through CRISPRi screens. Nat. Commun. 16, 4685 (2025).","journal-title":"Nat. Commun."},{"key":"1548_CR48","doi-asserted-by":"crossref","first-page":"923718","DOI":"10.3389\/fgeed.2022.923718","volume":"4","author":"CA Burnett","year":"2022","unstructured":"Burnett, C. A. et al. Examination of the cell cycle dependence of cytosine and adenine base editors. Front. Genome Ed. 4, 923718 (2022).","journal-title":"Front. Genome Ed."},{"key":"1548_CR49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1269\/jrr.08080","volume":"50","author":"S-I Yonekura","year":"2009","unstructured":"Yonekura, S.-I., Nakamura, N., Yonei, S. & Zhang-Akiyama, Q.-M. Generation, biological consequences and repair mechanisms of cytosine deamination in DNA. J. Radiat. Res. 50, 19\u201326 (2009).","journal-title":"J. Radiat. Res."},{"key":"1548_CR50","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/287560a0","volume":"287","author":"BK Duncan","year":"1980","unstructured":"Duncan, B. K. & Miller, J. H. Mutagenic deamination of cytosine residues in DNA. Nature 287, 560\u2013561 (1980).","journal-title":"Nature"},{"key":"1548_CR51","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0165-1110(90)90019-8","volume":"238","author":"M Ehrlich","year":"1990","unstructured":"Ehrlich, M., Zhang, X.-Y. & Inamdar, N. M. Spontaneous deamination of cytosine and 5-methylcytosine residues in DNA and replacement of 5-methylcytosine residues with cytosine residues. Mutat. Res. 238, 277\u2013286 (1990).","journal-title":"Mutat. Res."},{"key":"1548_CR52","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/s41587-021-00938-z","volume":"39","author":"LW Koblan","year":"2021","unstructured":"Koblan, L. W. et al. Development of a set of C\u2022G-to-G\u2022C transversion base editors from CRISPRi screens, target-library analysis, and machine learning. Nat. Biotechnol. 39, 1414\u20131425 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0378-1119(91)90030-F","volume":"99","author":"W Zhigang","year":"1991","unstructured":"Zhigang, W., Smith, D. G. & Mosbaugh, D. W. Overproduction and characterization of the uracil-DNA glycosylase inhibitor of bacteriophage PBS2. Gene 99, 31\u201337 (1991).","journal-title":"Gene"},{"key":"1548_CR54","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/cr.2017.111","volume":"27","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. Enhanced base editing by co-expression of free uracil DNA glycosylase inhibitor. Cell Res. 27, 1289\u20131292 (2017).","journal-title":"Cell Res."},{"key":"1548_CR55","doi-asserted-by":"crossref","first-page":"eaao4774","DOI":"10.1126\/sciadv.aao4774","volume":"3","author":"AC Komor","year":"2017","unstructured":"Komor, A. C. et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci. Adv. 3, eaao4774 (2017). This describes the development of the BE4 architecture for cytosine base editors, which is widely used now for most applications.","journal-title":"Sci. Adv."},{"key":"1548_CR56","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2300709","volume":"389","author":"R Chiesa","year":"2023","unstructured":"Chiesa, R. et al. Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 389, 899\u2013910 (2023). This describes the first base editing clinical trial, in which BE3 was used to engineer >chimeric antigen receptor (CAR) T cells to treat T cell acute lymphoblastic leukaemia, performed by academic researchers at the Great Ormond Street Hospital and University College London.","journal-title":"N. Engl. J. Med."},{"key":"1548_CR57","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.ymthe.2020.01.005","volume":"28","author":"CKW Lim","year":"2020","unstructured":"Lim, C. K. W. et al. Treatment of a mouse model of ALS by in vivo base editing. Mol. Ther. 28, 1177\u20131189 (2020).","journal-title":"Mol. Ther."},{"key":"1548_CR58","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41551-019-0501-5","volume":"4","author":"JM Levy","year":"2020","unstructured":"Levy, J. M. et al. Cytosine and adenine base editing of the brain, liver, retina, heart and skeletal muscle of mice via adeno-associated viruses. Nat. Biomed. Eng. 4, 97\u2013110 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1548_CR59","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.csbj.2021.04.051","volume":"19","author":"B Song","year":"2021","unstructured":"Song, B. et al. In vivo genome editing in single mammalian brain neurons through CRISPR\u2013Cas9 and cytosine base editors. Comput. Struct. Biotechnol. J. 19, 2477\u20132485 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1548_CR60","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04580-3","volume":"9","author":"W-H Yeh","year":"2018","unstructured":"Yeh, W.-H., Chiang, H., Rees, H. A., Edge, A. S. B. & Liu, D. R. In vivo base editing of post-mitotic sensory cells. Nat. Commun. 9, 2184 (2018).","journal-title":"Nat. Commun."},{"key":"1548_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15790","volume":"8","author":"HA Rees","year":"2017","unstructured":"Rees, H. A. et al. Improving the DNA specificity and applicability of base editing through protein engineering and protein delivery. Nat. Commun. 8, 15790 (2017).","journal-title":"Nat. Commun."},{"key":"1548_CR62","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1146\/annurev.biochem.71.110601.135501","volume":"71","author":"BL Bass","year":"2002","unstructured":"Bass, B. L. RNA Editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem. 71, 817\u2013846 (2002).","journal-title":"Annu. Rev. Biochem."},{"key":"1548_CR63","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1093\/emboj\/cdf362","volume":"21","author":"J Wolf","year":"2002","unstructured":"Wolf, J., Gerber, A. P. & Keller, W. tadA, an essential tRNA-specific adenosine deaminase from Escherichia coli. EMBO J. 21, 3841\u20133851 (2002).","journal-title":"EMBO J."},{"key":"1548_CR64","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.286.5442.1146","volume":"286","author":"AP Gerber","year":"1999","unstructured":"Gerber, A. P. & Keller, W. An adenosine deaminase that generates inosine at the wobble position of tRNAs. Science 286, 1146\u20131149 (1999).","journal-title":"Science"},{"key":"1548_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2004-5-2-209","volume":"5","author":"LP Keegan","year":"2004","unstructured":"Keegan, L. P., Leroy, A., Sproul, D. & O\u2019Connell, M. A. Adenosine deaminases acting on RNA (ADARs): RNA-editing enzymes. Genome Biol. 5, 209 (2004).","journal-title":"Genome Biol."},{"key":"1548_CR66","doi-asserted-by":"crossref","first-page":"13638","DOI":"10.1021\/bi701480f","volume":"46","author":"GK Schroeder","year":"2007","unstructured":"Schroeder, G. K. & Wolfenden, R. Rates of spontaneous disintegration of DNA and the rate enhancements produced by DNA glycosylases and deaminases. Biochemistry 46, 13638\u201313647 (2007).","journal-title":"Biochemistry"},{"key":"1548_CR67","doi-asserted-by":"crossref","unstructured":"Lindahl, T. DNA glycosylases, endonucleases for apurinic\/apyrimidinic sites, and base excision-repair. In Progress in Nucleic Acid Research and Molecular Biology Vol. 22 (ed. Cohn, W. E.) 135\u2013192 (Academic Press, 1979).","DOI":"10.1016\/S0079-6603(08)60800-4"},{"key":"1548_CR68","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/362709a0","volume":"362","author":"T Lindahl","year":"1993","unstructured":"Lindahl, T. Instability and decay of the primary structure of DNA. Nature 362, 709\u2013715 (1993).","journal-title":"Nature"},{"key":"1548_CR69","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.gde.2014.07.008","volume":"26","author":"I Alseth","year":"2014","unstructured":"Alseth, I., Dalhus, B. & Bj\u00f8r\u00e5s, M. Inosine in DNA and RNA. Curr. Opin. Genet. Dev. 26, 116\u2013123 (2014).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"1548_CR70","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/s41587-023-01821-9","volume":"42","author":"L Chen","year":"2024","unstructured":"Chen, L. et al. Adenine transversion editors enable precise, efficient A\u2022T-to-C\u2022G base editing in mammalian cells and embryos. Nat. Biotechnol. 42, 638\u2013650 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR71","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41551-019-0357-8","volume":"4","author":"C-Q Song","year":"2020","unstructured":"Song, C.-Q. et al. Adenine base editing in an adult mouse model of tyrosinaemia. Nat. Biomed. Eng. 4, 125\u2013130 (2020).","journal-title":"Nat. Biomed. Eng."},{"key":"1548_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04768-7","volume":"9","author":"Z Liu","year":"2018","unstructured":"Liu, Z. et al. Efficient generation of mouse models of human diseases via ABE- and BE-mediated base editing. Nat. Commun. 9, 2338 (2018).","journal-title":"Nat. Commun."},{"key":"1548_CR73","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/nbt.4148","volume":"36","author":"S-M Ryu","year":"2018","unstructured":"Ryu, S.-M. et al. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat. Biotechnol. 36, 536\u2013539 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR74","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1073\/pnas.0912629107","volume":"107","author":"M Lynch","year":"2010","unstructured":"Lynch, M. Rate molecular spectrum, and consequences of human mutation. Proc. Natl Acad. Sci. USA 107, 961\u2013968 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1548_CR75","doi-asserted-by":"crossref","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum, M. J. et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42, D980\u2013D985 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1548_CR76","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nbt.4172","volume":"36","author":"LW Koblan","year":"2018","unstructured":"Koblan, L. W. et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat. Biotechnol. 36, 843\u2013846 (2018). This describes the development of the BE4max and ABE7.10max architectures, which are widely adopted now.","journal-title":"Nat. Biotechnol."},{"key":"1548_CR77","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/nbt.4194","volume":"36","author":"MP Zafra","year":"2018","unstructured":"Zafra, M. P. et al. Optimized base editors enable efficient editing in cells, organoids and mice. Nat. Biotechnol. 36, 888\u2013893 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR78","doi-asserted-by":"crossref","unstructured":"Osgood, N. R. B. et al. Genome editing with programmable base editors in human cells. In Methods in Enzymology Ch. 14, Vol. 712 (eds Ke, A. & Tang, W.) 351\u2013404 (Academic Press, 2025).","DOI":"10.1016\/bs.mie.2025.01.001"},{"key":"1548_CR79","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41596-020-00450-9","volume":"16","author":"TP Huang","year":"2021","unstructured":"Huang, T. P., Newby, G. A. & Liu, D. R. Precision genome editing using cytosine and adenine base editors in mammalian cells. Nat. Protoc. 16, 1089\u20131128 (2021).","journal-title":"Nat. Protoc."},{"key":"1548_CR80","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR\u2013Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR81","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/1873-3468.12707","volume":"591","author":"KT Jensen","year":"2017","unstructured":"Jensen, K. T. et al. Chromatin accessibility and guide sequence secondary structure affect CRISPR\u2013Cas9 gene editing efficiency. FEBS Lett. 591, 1892\u20131901 (2017).","journal-title":"FEBS Lett."},{"key":"1548_CR82","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1126\/science.1246981","volume":"343","author":"T Wang","year":"2014","unstructured":"Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR\u2013Cas9 system. Science 343, 80\u201384 (2014).","journal-title":"Science"},{"key":"1548_CR83","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.copbio.2018.07.005","volume":"55","author":"SA Verkuijl","year":"2019","unstructured":"Verkuijl, S. A. & Rots, M. G. The influence of eukaryotic chromatin state on CRISPR\u2013Cas9 editing efficiencies. Curr. Opin. Biotechnol. 55, 68\u201373 (2019).","journal-title":"Curr. Opin. Biotechnol."},{"key":"1548_CR84","doi-asserted-by":"crossref","first-page":"bbad205","DOI":"10.1093\/bib\/bbad205","volume":"24","author":"G Giner","year":"2023","unstructured":"Giner, G., Ikram, S., Herold, M. J. & Papenfuss, A. T. A systematic review of computational methods for designing efficient guides for CRISPR DNA base editor systems. Brief. Bioinform. 24, bbad205 (2023).","journal-title":"Brief. Bioinform."},{"key":"1548_CR85","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2018.06.052","volume":"174","author":"DA Cusanovich","year":"2018","unstructured":"Cusanovich, D. A. et al. A single-cell atlas of in vivo mammalian chromatin accessibility. Cell 174, 1309\u20131324 (2018).","journal-title":"Cell"},{"key":"1548_CR86","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1016\/j.cell.2021.10.024","volume":"184","author":"K Zhang","year":"2021","unstructured":"Zhang, K. et al. A single-cell atlas of chromatin accessibility in the human genome. Cell 184, 5985\u20136001 (2021).","journal-title":"Cell"},{"key":"1548_CR87","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41589-022-01163-8","volume":"19","author":"L Chen","year":"2023","unstructured":"Chen, L. et al. Engineering a precise adenine base editor with minimal bystander editing. Nat. Chem. Biol. 19, 101\u2013110 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"1548_CR88","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/nbt.4199","volume":"36","author":"JM Gehrke","year":"2018","unstructured":"Gehrke, J. M. et al. An APOBEC3A\u2013Cas9 base editor with minimized bystander and off-target activities. Nat. Biotechnol. 36, 977\u2013982 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR89","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41587-025-02678-w","volume":"44","author":"Y Wu","year":"2026","unstructured":"Wu, Y., Xiao, Y.-L. & Tang, W. High-precision cytosine base editors by evolving nucleic-acid-recognition hotspots in deaminase. Nat. Biotechnol. 44, 587\u2013601 (2026).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR90","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1016\/j.ymthe.2022.07.010","volume":"30","author":"T Tu","year":"2022","unstructured":"Tu, T. et al. A precise and efficient adenine base editor. Mol. Ther. 30, 2933\u20132941 (2022).","journal-title":"Mol. Ther."},{"key":"1548_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01545-y","author":"MN Whittaker","year":"2025","unstructured":"Whittaker, M. N. et al. Improved specificity and efficiency of in vivo adenine base editing therapies with hybrid guide RNAs. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-025-01545-y (2025).","journal-title":"Nat. Biomed. Eng."},{"key":"1548_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-020-00849-6","volume":"18","author":"Z Liu","year":"2020","unstructured":"Liu, Z. et al. Precise base editing with CC context-specificity using engineered human APOBEC3G\u2013nCas9 fusions. BMC Biol. 18, 111 (2020).","journal-title":"BMC Biol."},{"key":"1548_CR93","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nbt.3803","volume":"35","author":"YB Kim","year":"2017","unstructured":"Kim, Y. B. et al. Increasing the genome-targeting scope and precision of base editing with engineered Cas9\u2013cytidine deaminase fusions. Nat. Biotechnol. 35, 371\u2013376 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR94","doi-asserted-by":"crossref","first-page":"aaf8729","DOI":"10.1126\/science.aaf8729","volume":"353","author":"K Nishida","year":"2016","unstructured":"Nishida, K. et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, aaf8729 (2016).","journal-title":"Science"},{"key":"1548_CR95","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1038\/nmeth.4038","volume":"13","author":"GT Hess","year":"2016","unstructured":"Hess, G. T. et al. Directed evolution using dCas9-targeted somatic hypermutation in mammalian cells. Nat. Methods 13, 1036\u20131042 (2016).","journal-title":"Nat. Methods"},{"key":"1548_CR96","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/nmeth.4027","volume":"13","author":"Y Ma","year":"2016","unstructured":"Ma, Y. et al. Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells. Nat. Methods 13, 1029\u20131035 (2016).","journal-title":"Nat. Methods"},{"key":"1548_CR97","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nbt.4198","volume":"36","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Efficient base editing in methylated regions with a human APOBEC3A\u2013Cas9 fusion. Nat. Biotechnol. 36, 946\u2013949 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR98","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1111\/pbi.70000","volume":"23","author":"DF Contiliani","year":"2025","unstructured":"Contiliani, D. F. et al. Harnessing novel cytidine deaminases from the animal kingdom for robust multiplexed base editing in rice. Plant Biotechnol. J. 23, 1702\u20131712 (2025).","journal-title":"Plant Biotechnol. J."},{"key":"1548_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15887-5","volume":"11","author":"Y Yu","year":"2020","unstructured":"Yu, Y. et al. Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity. Nat. Commun. 11, 2052 (2020).","journal-title":"Nat. Commun."},{"key":"1548_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52483-3","volume":"15","author":"N Zhao","year":"2024","unstructured":"Zhao, N. et al. Evolved cytidine and adenine base editors with high precision and minimized off-target activity by a continuous directed evolution system in mammalian cells. Nat. Commun. 15, 8140 (2024).","journal-title":"Nat. Commun."},{"key":"1548_CR101","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41587-022-01611-9","volume":"41","author":"DK Lam","year":"2023","unstructured":"Lam, D. K. et al. Improved cytosine base editors generated from TadA variants. Nat. Biotechnol. 41, 686\u2013697 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR102","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41587-022-01533-6","volume":"41","author":"ME Neugebauer","year":"2023","unstructured":"Neugebauer, M. E. et al. Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity. Nat. Biotechnol. 41, 673\u2013685 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45969-7","volume":"15","author":"E Zhang","year":"2024","unstructured":"Zhang, E., Neugebauer, M. E., Krasnow, N. A. & Liu, D. R. Phage-assisted evolution of highly active cytosine base editors with enhanced selectivity and minimal sequence context preference. Nat. Commun. 15, 1697 (2024).","journal-title":"Nat. Commun."},{"key":"1548_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32157-8","volume":"13","author":"A Li","year":"2022","unstructured":"Li, A. et al. Cytosine base editing systems with minimized off-target effect and molecular size. Nat. Commun. 13, 4531 (2022).","journal-title":"Nat. Commun."},{"key":"1548_CR105","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s41589-024-01595-4","volume":"20","author":"L Yang","year":"2024","unstructured":"Yang, L. et al. Engineering APOBEC3A deaminase for highly accurate and efficient base editing. Nat. Chem. Biol. 20, 1176\u20131187 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"1548_CR106","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.molcel.2020.07.005","volume":"79","author":"S Jin","year":"2020","unstructured":"Jin, S. et al. Rationally designed APOBEC3B cytosine base editors with improved specificity. Mol. Cell 79, 728\u2013740 (2020).","journal-title":"Mol. Cell"},{"key":"1548_CR107","doi-asserted-by":"crossref","first-page":"eaba1773","DOI":"10.1126\/sciadv.aba1773","volume":"6","author":"S Lee","year":"2020","unstructured":"Lee, S. et al. Single C-to-T substitution using engineered APOBEC3G-nCas9 base editors with minimum genome- and transcriptome-wide off-target effects. Sci. Adv. 6, eaba1773 (2020).","journal-title":"Sci. Adv."},{"key":"1548_CR108","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41587-019-0193-0","volume":"37","author":"BW Thuronyi","year":"2019","unstructured":"Thuronyi, B. W. et al. Continuous evolution of base editors with expanded target compatibility and improved activity. Nat. Biotechnol. 37, 1070\u20131079 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR109","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1021\/bi0522394","volume":"45","author":"J Kim","year":"2006","unstructured":"Kim, J. et al. Structural and kinetic characterization of Escherichia coli TadA, the wobble-specific tRNA deaminase. Biochemistry 45, 6407\u20136416 (2006).","journal-title":"Biochemistry"},{"key":"1548_CR110","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nsmb1047","volume":"13","author":"HC Losey","year":"2006","unstructured":"Losey, H. C., Ruthenburg, A. J. & Verdine, G. L. Crystal structure of Staphylococcus aureus tRNA adenosine deaminase TadA in complex with RNA. Nat. Struct. Mol. Biol. 13, 153\u2013159 (2006).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1548_CR111","doi-asserted-by":"crossref","first-page":"eaaz2309","DOI":"10.1126\/sciadv.aaz2309","volume":"6","author":"KL Rallapalli","year":"2020","unstructured":"Rallapalli, K. L., Komor, A. C. & Paesani, F. Computer simulations explain mutation-induced effects on the DNA editing by adenine base editors. Sci. Adv. 6, eaaz2309 (2020).","journal-title":"Sci. Adv."},{"key":"1548_CR112","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41587-019-0236-6","volume":"37","author":"J Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald, J. et al. CRISPR DNA base editors with reduced RNA off-target and self-editing activities. Nat. Biotechnol. 37, 1041\u20131048 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR113","doi-asserted-by":"crossref","first-page":"13931","DOI":"10.1093\/nar\/gkae1066","volume":"52","author":"PR Arantes","year":"2024","unstructured":"Arantes, P. R. et al. Dimerization of the deaminase domain and locking interactions with Cas9 boost base editing efficiency in ABE8e. Nucleic Acids Res. 52, 13931\u201313944 (2024).","journal-title":"Nucleic Acids Res."},{"key":"1548_CR114","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","volume":"38","author":"MF Richter","year":"2020","unstructured":"Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883\u2013891 (2020). This describes the development of ABE8e, which has been widely used for various applications, including clinical work.","journal-title":"Nat. Biotechnol."},{"key":"1548_CR115","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","volume":"38","author":"NM Gaudelli","year":"2020","unstructured":"Gaudelli, N. M. et al. Directed evolution of adenine base editors with increased activity and therapeutic application. Nat. Biotechnol. 38, 892\u2013900 (2020). This describes the development of ABE8.20, ABE8.8 and others, which have been widely used for various applications, including clinical work.","journal-title":"Nat. Biotechnol."},{"key":"1548_CR116","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41587-023-01994-3","volume":"42","author":"Y-L Xiao","year":"2024","unstructured":"Xiao, Y.-L., Wu, Y. & Tang, W. An adenine base editor variant expands context compatibility. Nat. Biotechnol. 42, 1442\u20131453 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR117","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429\u2013434 (2021). This describes the first demonstration in non-human primates of base editing to knock out PCSK9 and lower cholesterol, performed by VERVE Therapeutics.","journal-title":"Nature"},{"key":"1548_CR118","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa2504835","volume":"394","author":"AO Gupta","year":"2026","unstructured":"Gupta, A. O. et al. Base editing of HBG1 and HBG2 promoters for sickle cell disease. N. Engl. J. Med. 394, 1824\u20131835 (2026). This describes the results of the Risto-Cell clinical trial, a base editing treatment for sickle cell disease, performed by Beam Therapeutics.","journal-title":"N. Engl. J. Med."},{"key":"1548_CR119","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","volume":"392","author":"K Musunuru","year":"2025","unstructured":"Musunuru, K. et al. Patient-specific in vivo gene editing to treat a rare genetic disease. N. Engl. J. Med. 392, 2235\u20132243 (2025). This describes the development of a bespoke base editing strategy to treat an infant with CPS1 deficiency, a urea cycle disorder, performed by academic researchers at the Children\u2019s Hospital of Philadelphia and University of Pennsylvania.","journal-title":"N. Engl. J. Med."},{"key":"1548_CR120","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1126\/science.aas9129","volume":"361","author":"H Nishimasu","year":"2018","unstructured":"Nishimasu, H. et al. Engineered CRISPR\u2013Cas9 nuclease with expanded targeting space. Science 361, 1259\u20131262 (2018).","journal-title":"Science"},{"key":"1548_CR121","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.aba8853","volume":"368","author":"RT Walton","year":"2020","unstructured":"Walton, R. T., Christie, K. A., Whittaker, M. N. & Kleinstiver, B. P. Unconstrained genome targeting with near-PAMless engineered CRISPR\u2013Cas9 variants. Science 368, 290\u2013296 (2020).","journal-title":"Science"},{"key":"1548_CR122","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/s41551-022-00911-4","volume":"6","author":"JR Davis","year":"2022","unstructured":"Davis, J. R. et al. Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors. Nat. Biomed. Eng. 6, 1272\u20131283 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"1548_CR123","doi-asserted-by":"crossref","first-page":"809922","DOI":"10.3389\/fcell.2022.809922","volume":"10","author":"S Wu","year":"2022","unstructured":"Wu, S. et al. Two compact Cas9 ortholog-based cytosine base editors expand the dna targeting scope and applications in vitro and in vivo. Front. Cell Dev. Biol. 10, 809922 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"1548_CR124","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.molcel.2018.12.003","volume":"73","author":"A Edraki","year":"2019","unstructured":"Edraki, A. et al. A compact, high-accuracy Cas9 with a dinucleotide PAM for in vivo genome editing. Mol. Cell 73, 714\u2013726 (2019).","journal-title":"Mol. Cell"},{"key":"1548_CR125","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/genbio.2022.0015","volume":"1","author":"H Zhang","year":"2022","unstructured":"Zhang, H. et al. Adenine base editing in vivo with a single adeno-associated virus vector. GEN Biotechnol. 1, 285\u2013299 (2022).","journal-title":"GEN Biotechnol."},{"key":"1548_CR126","doi-asserted-by":"publisher","unstructured":"Evanoff, M., Korpal, S., Krill, Z. D., Cowan, Q. T. & Komor, A. C. Precise, minimally evolved adenine base editors generated through mutation reversion analysis. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-026-03045-z (2026).","DOI":"10.1038\/s41587-026-03045-z"},{"key":"1548_CR127","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature14592","volume":"523","author":"BP Kleinstiver","year":"2015","unstructured":"Kleinstiver, B. P. et al. Engineered CRISPR\u2013Cas9 nucleases with altered PAM specificities. Nature 523, 481\u2013485 (2015).","journal-title":"Nature"},{"key":"1548_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63609-6","volume":"16","author":"I Valdez","year":"2025","unstructured":"Valdez, I. et al. A streamlined base editor engineering strategy to reduce bystander editing. Nat. Commun. 16, 8115 (2025).","journal-title":"Nat. Commun."},{"key":"1548_CR129","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41586-025-09021-y","volume":"643","author":"RA Silverstein","year":"2025","unstructured":"Silverstein, R. A. et al. Custom CRISPR\u2013Cas9 PAM variants via scalable engineering and machine learning. Nature 643, 539\u2013550 (2025).","journal-title":"Nature"},{"key":"1548_CR130","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.ymthe.2022.01.040","volume":"30","author":"MS Packer","year":"2022","unstructured":"Packer, M. S. et al. Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency. Mol. Ther. 30, 1396\u20131406 (2022). This describes the development of a base editing strategy to treat alpha-1 antitrypsin deficiency, performed by Beam Therapeutics.","journal-title":"Mol. Ther."},{"key":"1548_CR131","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41587-019-0134-y","volume":"37","author":"TP Huang","year":"2019","unstructured":"Huang, T. P. et al. Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors. Nat. Biotechnol. 37, 626\u2013631 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR132","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/crispr.2020.0144","volume":"4","author":"SH Chu","year":"2021","unstructured":"Chu, S. H. et al. Rationally designed base editors for precise editing of the sickle cell disease mutation. CRISPR J. 4, 169\u2013177 (2021).","journal-title":"CRISPR J."},{"key":"1548_CR133","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41392-019-0072-7","volume":"4","author":"Y Wang","year":"2019","unstructured":"Wang, Y., Zhou, L., Liu, N. & Yao, S. BE-PIGS: a base-editing tool with deaminases inlaid into Cas9 PI domain significantly expanded the editing scope. Signal. Transduct. Target. Ther. 4, 36 (2019).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"1548_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45763-5","volume":"15","author":"N Bamidele","year":"2024","unstructured":"Bamidele, N. et al. Domain-inlaid Nme2Cas9 adenine base editors with improved activity and targeting scope. Nat. Commun. 15, 1458 (2024).","journal-title":"Nat. Commun."},{"key":"1548_CR135","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18715-y","volume":"11","author":"MT Nguyen Tran","year":"2020","unstructured":"Nguyen Tran, M. T. et al. Engineering domain-inlaid SaCas9 adenine base editors with reduced RNA off-targets and increased on-target DNA editing. Nat. Commun. 11, 4871 (2020).","journal-title":"Nat. Commun."},{"key":"1548_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56655-7","volume":"16","author":"L Hu","year":"2025","unstructured":"Hu, L. et al. A universal and wide-range cytosine base editor via domain-inlaid and fidelity-optimized CRISPR\u2013FrCas9. Nat. Commun. 16, 1260 (2025).","journal-title":"Nat. Commun."},{"key":"1548_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-023-01754-4","volume":"21","author":"D Zhao","year":"2023","unstructured":"Zhao, D. et al. Engineered domain-inlaid Nme2Cas9 adenine base editors with increased on-target DNA editing and targeting scope. BMC Biol. 21, 250 (2023).","journal-title":"BMC Biol."},{"key":"1548_CR138","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1126\/science.aax1827","volume":"364","author":"HR Kempton","year":"2019","unstructured":"Kempton, H. R. & Qi, L. S. When genome editing goes off-target. Science 364, 234\u2013236 (2019).","journal-title":"Science"},{"key":"1548_CR139","doi-asserted-by":"crossref","first-page":"100480","DOI":"10.1016\/j.cobme.2023.100480","volume":"28","author":"X Rao","year":"2023","unstructured":"Rao, X., Zhao, H., Shao, C. & Yi, C. Characterizing off-target effects of genome editors. Curr. Opin. Biomed. Eng. 28, 100480 (2023).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"1548_CR140","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1021\/acs.biochem.9b00573","volume":"58","author":"S Park","year":"2019","unstructured":"Park, S. & Beal, P. A. Off-target editing by CRISPR-guided DNA base editors. Biochemistry 58, 3727\u20133734 (2019).","journal-title":"Biochemistry"},{"key":"1548_CR141","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00294-021-01211-1","volume":"68","author":"YS Slesarenko","year":"2022","unstructured":"Slesarenko, Y. S., Lavrov, A. V. & Smirnikhina, S. A. Off-target effects of base editors: what we know and how we can reduce it. Curr. Genet. 68, 39\u201348 (2022).","journal-title":"Curr. Genet."},{"key":"1548_CR142","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","volume":"31","author":"PD Hsu","year":"2013","unstructured":"Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827\u2013832 (2013).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR143","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07988-z","volume":"10","author":"P Liang","year":"2019","unstructured":"Liang, P. et al. Genome-wide profiling of adenine base editor specificity by EndoV-seq. Nat. Commun. 10, 67 (2019).","journal-title":"Nat. Commun."},{"key":"1548_CR144","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nbt.3852","volume":"35","author":"D Kim","year":"2017","unstructured":"Kim, D. et al. Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat. Biotechnol. 35, 475\u2013480 (2017).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR145","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41587-019-0050-1","volume":"37","author":"D Kim","year":"2019","unstructured":"Kim, D., Kim, D., Lee, G., Cho, S.-I. & Kim, J.-S. Genome-wide target specificity of CRISPR RNA-guided adenine base editors. Nat. Biotechnol. 37, 430\u2013435 (2019).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41004-3","volume":"14","author":"C Zhang","year":"2023","unstructured":"Zhang, C. et al. Prediction of base editor off-targets by deep learning. Nat. Commun. 14, 5358 (2023).","journal-title":"Nat. Commun."},{"key":"1548_CR147","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/s41589-023-01279-5","volume":"19","author":"Y Kim","year":"2023","unstructured":"Kim, Y. et al. Sniper2L is a high-fidelity Cas9 variant with high activity. Nat. Chem. Biol. 19, 972\u2013980 (2023).","journal-title":"Nat. Chem. Biol."},{"key":"1548_CR148","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aad5227","volume":"351","author":"IM Slaymaker","year":"2016","unstructured":"Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84\u201388 (2016).","journal-title":"Science"},{"key":"1548_CR149","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nature16526","volume":"529","author":"BP Kleinstiver","year":"2016","unstructured":"Kleinstiver, B. P. et al. High-fidelity CRISPR\u2013Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490\u2013495 (2016).","journal-title":"Nature"},{"key":"1548_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05477-x","volume":"9","author":"JK Lee","year":"2018","unstructured":"Lee, J. K. et al. Directed evolution of CRISPR\u2013Cas9 to increase its specificity. Nat. Commun. 9, 3048 (2018).","journal-title":"Nat. Commun."},{"key":"1548_CR151","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature24268","volume":"550","author":"JS Chen","year":"2017","unstructured":"Chen, J. S. et al. Enhanced proofreading governs CRISPR\u2013Cas9 targeting accuracy. Nature 550, 407\u2013410 (2017).","journal-title":"Nature"},{"key":"1548_CR152","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas, C. A. et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat. Med. 24, 1216\u20131224 (2018).","journal-title":"Nat. Med."},{"key":"1548_CR153","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae, S., Park, J. & Kim, J.-S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473\u20131475 (2014).","journal-title":"Bioinformatics"},{"key":"1548_CR154","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1093\/nar\/gkac161","volume":"50","author":"A Pallaseni","year":"2022","unstructured":"Pallaseni, A. et al. Predicting base editing outcomes using position-specific sequence determinants. Nucleic Acids Res. 50, 3551\u20133564 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1548_CR155","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41551-017-0178-6","volume":"2","author":"J Listgarten","year":"2018","unstructured":"Listgarten, J. et al. Prediction of off-target activities for the end-to-end design of CRISPR guide RNAs. Nat. Biomed. Eng. 2, 38\u201347 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"1548_CR156","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nbt.3117","volume":"33","author":"SQ Tsai","year":"2015","unstructured":"Tsai, S. Q. et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR\u2013Cas nucleases. Nat. Biotechnol. 33, 187\u2013197 (2015).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR157","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/nmeth.4284","volume":"14","author":"P Cameron","year":"2017","unstructured":"Cameron, P. et al. Mapping the genomic landscape of CRISPR\u2013Cas9 cleavage. Nat. Methods 14, 600\u2013606 (2017).","journal-title":"Nat. Methods"},{"key":"1548_CR158","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/nmeth.4278","volume":"14","author":"SQ Tsai","year":"2017","unstructured":"Tsai, S. Q. et al. CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR\u2013Cas9 nuclease off-targets. Nat. Methods 14, 607\u2013614 (2017).","journal-title":"Nat. Methods"},{"key":"1548_CR159","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1038\/s41596-018-0055-0","volume":"13","author":"CR Lazzarotto","year":"2018","unstructured":"Lazzarotto, C. R. et al. Defining CRISPR\u2013Cas9 genome-wide nuclease activities with CIRCLE-seq. Nat. Protoc. 13, 2615\u20132642 (2018).","journal-title":"Nat. Protoc."},{"key":"1548_CR160","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41592-021-01172-w","volume":"18","author":"Z Lei","year":"2021","unstructured":"Lei, Z. et al. Detect-seq reveals out-of-protospacer editing and target-strand editing by cytosine base editors. Nat. Methods 18, 643\u2013651 (2021).","journal-title":"Nat. Methods"},{"key":"1548_CR161","doi-asserted-by":"publisher","unstructured":"Lazzarotto, C. R. et al. Sensitive and unbiased genome-wide profiling of base-editor-induced off-target activity using CHANGE-seq-BE. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-025-02948-7 (2026).","DOI":"10.1038\/s41587-025-02948-7"},{"key":"1548_CR162","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1126\/science.aav9973","volume":"364","author":"E Zuo","year":"2019","unstructured":"Zuo, E. et al. Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science 364, 289\u2013292 (2019).","journal-title":"Science"},{"key":"1548_CR163","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1126\/science.aaw7166","volume":"364","author":"S Jin","year":"2019","unstructured":"Jin, S. et al. Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science 364, 292\u2013295 (2019).","journal-title":"Science"},{"key":"1548_CR164","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1038\/s41596-020-0361-1","volume":"15","author":"E Zuo","year":"2020","unstructured":"Zuo, E. et al. GOTI, a method to identify genome-wide off-target effects of genome editing in mouse embryos. Nat. Protoc. 15, 3009\u20133029 (2020).","journal-title":"Nat. Protoc."},{"key":"1548_CR165","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/s41587-020-0414-6","volume":"38","author":"JL Doman","year":"2020","unstructured":"Doman, J. L., Raguram, A., Newby, G. A. & Liu, D. R. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat. Biotechnol. 38, 620\u2013628 (2020).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR166","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52485-1","volume":"15","author":"G Li","year":"2024","unstructured":"Li, G. et al. Engineering TadA ortholog-derived cytosine base editor without motif preference and adenosine activity limitation. Nat. Commun. 15, 8090 (2024).","journal-title":"Nat. Commun."},{"key":"1548_CR167","doi-asserted-by":"crossref","first-page":"eaax5717","DOI":"10.1126\/sciadv.aax5717","volume":"5","author":"HA Rees","year":"2019","unstructured":"Rees, H. A., Wilson, C., Doman, J. L. & Liu, D. R. Analysis and minimization of cellular RNA editing by DNA adenine base editors. Sci. Adv. 5, eaax5717 (2019). This describes the identification of the V106W mutation in TadA, which can reduce off-target editing.","journal-title":"Sci. Adv."},{"key":"1548_CR168","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41586-019-1314-0","volume":"571","author":"C Zhou","year":"2019","unstructured":"Zhou, C. et al. Off-target RNA mutation induced by DNA base editing and its elimination by mutagenesis. Nature 571, 275\u2013278 (2019).","journal-title":"Nature"},{"key":"1548_CR169","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41586-019-1161-z","volume":"569","author":"J Gr\u00fcnewald","year":"2019","unstructured":"Gr\u00fcnewald, J. et al. Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors. Nature 569, 433\u2013437 (2019).","journal-title":"Nature"},{"key":"1548_CR170","doi-asserted-by":"crossref","first-page":"eabg2661","DOI":"10.1126\/sciadv.abg2661","volume":"7","author":"H-K Jang","year":"2021","unstructured":"Jang, H.-K. et al. High-purity production and precise editing of DNA base editing ribonucleoproteins. Sci. Adv. 7, eabg2661 (2021).","journal-title":"Sci. Adv."},{"key":"1548_CR171","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41586-021-03609-w","volume":"595","author":"GA Newby","year":"2021","unstructured":"Newby, G. A. et al. Base editing of haematopoietic stem cells rescues sickle cell disease in mice. Nature 595, 295\u2013302 (2021). This describes the development of a base editing strategy to treat sick cell disease by directly converting the pathogenic mutation into a non-wild type, but benign variant (E6A, also known as the Makassar variant), performed by academic researchers at St. Jude Children\u2019s Research Hospital and the Broad Institute.","journal-title":"Nature"},{"key":"1548_CR172","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34493-1","volume":"13","author":"P Antoniou","year":"2022","unstructured":"Antoniou, P. et al. Base-editing-mediated dissection of a \u03b3-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression. Nat. Commun. 13, 6618 (2022).","journal-title":"Nat. Commun."},{"key":"1548_CR173","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64562-0","volume":"16","author":"Z Song","year":"2025","unstructured":"Song, Z. et al. Noncanonical target-strand cytosine base editing via engineered Un1Cas12f1 platform. Nat. Commun. 16, 9499 (2025).","journal-title":"Nat. Commun."},{"key":"1548_CR174","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2021.12.021","volume":"185","author":"S Banskota","year":"2022","unstructured":"Banskota, S. et al. Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell 185, 250\u2013265 (2022).","journal-title":"Cell"},{"key":"1548_CR175","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41587-024-02467-x","volume":"43","author":"A Raguram","year":"2025","unstructured":"Raguram, A., An, M., Chen, P. Z. & Liu, D. R. Directed evolution of engineered virus-like particles with improved production and transduction efficiencies. Nat. Biotechnol. 43, 1635\u20131647 (2025).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR176","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","volume":"26","author":"J Zeng","year":"2020","unstructured":"Zeng, J. et al. Therapeutic base editing of human hematopoietic stem cells. Nat. Med. 26, 535\u2013541 (2020).","journal-title":"Nat. Med."},{"key":"1548_CR177","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35508-7","volume":"14","author":"J Liao","year":"2023","unstructured":"Liao, J. et al. Therapeutic adenine base editing of human hematopoietic stem cells. Nat. Commun. 14, 207 (2023).","journal-title":"Nat. Commun."},{"key":"1548_CR178","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41587-020-0592-2","volume":"39","author":"D Zhao","year":"2021","unstructured":"Zhao, D. et al. Glycosylase base editors enable C-to-A and C-to-G base changes. Nat. Biotechnol. 39, 35\u201340 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR179","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41587-020-0609-x","volume":"39","author":"IC Kurt","year":"2021","unstructured":"Kurt, I. C. et al. CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nat. Biotechnol. 39, 41\u201346 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR180","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41587-022-01595-6","volume":"41","author":"Tong","year":"2023","unstructured":"Tong et al. Programmable A-to-Y base editing by fusing an adenine base editor with an N-methylpurine DNA glycosylase. Nat. Biotechnol. 41, 1080\u20131084 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR181","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1038\/s41587-023-02050-w","volume":"42","author":"L Ye","year":"2024","unstructured":"Ye, L. et al. Glycosylase-based base editors for efficient T-to-G and C-to-G editing in mammalian cells. Nat. Biotechnol. 42, 1538\u20131547 (2024).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49343-5","volume":"15","author":"H Tong","year":"2024","unstructured":"Tong, H. et al. Development of deaminase-free T-to-S base editor and C-to-G base editor by engineered human uracil DNA glycosylase. Nat. Commun. 15, 4897 (2024).","journal-title":"Nat. Commun."},{"key":"1548_CR183","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/pbi.14583","volume":"23","author":"Y Wu","year":"2025","unstructured":"Wu, Y. et al. Targeted deaminase-free T-to-G and C-to-K base editing in rice by fused human uracil DNA glycosylase variants. Plant Biotechnol. J. 23, 1257\u20131259 (2025).","journal-title":"Plant Biotechnol. J."},{"key":"1548_CR184","doi-asserted-by":"crossref","first-page":"nwad143","DOI":"10.1093\/nsr\/nwad143","volume":"10","author":"H Tong","year":"2023","unstructured":"Tong, H. et al. Programmable deaminase-free base editors for G-to-Y conversion by engineered glycosylase. Natl Sci. Rev. 10, nwad143 (2023).","journal-title":"Natl Sci. Rev."},{"key":"1548_CR185","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1111\/pbi.70063","volume":"23","author":"Y Kuang","year":"2025","unstructured":"Kuang, Y. et al. Developing glycosylase-based T-to-G and C-to-K base editors in rice. Plant Biotechnol. J. 23, 2358\u20132360 (2025).","journal-title":"Plant Biotechnol. J."},{"key":"1548_CR186","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1056\/NEJMoa2601283","volume":"395","author":"SB Vafai","year":"2026","unstructured":"Vafai, S. B. et al. In vivo base editing of PCSK9 with VERVE-102 for hypercholesterolemia. N. Engl. J. Med. 395, 648-659 (2026). This describes the results from the base editing clinical trial in which ABE8.8 was used to knock out PCSK9 to treat hypercholesterolaemia, performed by Verve Therapeutics.","journal-title":"N. Engl. J. Med."},{"key":"1548_CR187","doi-asserted-by":"crossref","first-page":"1314077","DOI":"10.3389\/fddsv.2023.1314077","volume":"3","author":"MWY Southey","year":"2023","unstructured":"Southey, M. W. Y. & Brunavs, M. Introduction to small molecule drug discovery and preclinical development. Front. Drug Discov. 3, 1314077 (2023).","journal-title":"Front. Drug Discov."},{"key":"1548_CR188","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","volume":"18","author":"Z Wu","year":"2010","unstructured":"Wu, Z., Yang, H. & Colosi, P. Effect of genome size on AAV vector packaging. Mol. Ther. 18, 80\u201386 (2010).","journal-title":"Mol. Ther."},{"key":"1548_CR189","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1016\/j.cell.2022.03.045","volume":"185","author":"A Raguram","year":"2022","unstructured":"Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell 185, 2806\u20132827 (2022).","journal-title":"Cell"},{"key":"1548_CR190","doi-asserted-by":"crossref","first-page":"102201","DOI":"10.1016\/j.omtn.2024.102201","volume":"35","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Engineering miniature CRISPR\u2013Cas Un1Cas12f1 for efficient base editing. Mol. Ther. Nucleic Acids 35, 102201 (2024).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1548_CR191","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/s41592-023-01898-9","volume":"20","author":"D Han","year":"2023","unstructured":"Han, D. et al. Development of miniature base editors using engineered IscB nickase. Nat. Methods 20, 1029\u20131036 (2023).","journal-title":"Nat. Methods"},{"key":"1548_CR192","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41589-024-01706-1","volume":"21","author":"Q Xiao","year":"2025","unstructured":"Xiao, Q. et al. Engineered IscB\u2013\u03c9RNA system with expanded target range for base editing. Nat. Chem. Biol. 21, 100\u2013108 (2025).","journal-title":"Nat. Chem. Biol."},{"key":"1548_CR193","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1038\/s41589-024-01670-w","volume":"20","author":"L Han","year":"2024","unstructured":"Han, L. et al. Engineering miniature IscB nickase for robust base editing with broad targeting range. Nat. Chem. Biol. 20, 1629\u20131639 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"1548_CR194","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/s41589-024-01669-3","volume":"20","author":"H Yan","year":"2024","unstructured":"Yan, H. et al. Assessing and engineering the IscB\u2013\u03c9RNA system for programmed genome editing. Nat. Chem. Biol. 20, 1617\u20131628 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"1548_CR195","doi-asserted-by":"crossref","first-page":"114973","DOI":"10.1016\/j.celrep.2024.114973","volume":"43","author":"R Guo","year":"2024","unstructured":"Guo, R. et al. Engineered IscB-\u03c9RNA system with improved base editing efficiency for disease correction via single AAV delivery in mice. Cell Rep. 43, 114973 (2024).","journal-title":"Cell Rep."},{"key":"1548_CR196","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-71327-w","volume":"17","author":"J Lu","year":"2026","unstructured":"Lu, J. et al. Miniature and versatile genome regulation TnpB-\u03c9RNA toolkits facilitate cancer immunotherapy. Nat. Commun. 17, 4667 (2026).","journal-title":"Nat. Commun."},{"key":"1548_CR197","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1038\/s41592-024-02418-z","volume":"21","author":"KF Marquart","year":"2024","unstructured":"Marquart, K. F. et al. Effective genome editing with an enhanced ISDra2 TnpB system and deep learning-predicted \u03c9RNAs. Nat. Methods 21, 2084\u20132093 (2024).","journal-title":"Nat. Methods"},{"key":"1548_CR198","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41589-025-01902-7","volume":"22","author":"Y Wei","year":"2026","unstructured":"Wei, Y. et al. Engineering eukaryotic transposon-encoded Fanzor2 system for genome editing in mammals. Nat. Chem. Biol. 22, 48\u201357 (2026).","journal-title":"Nat. Chem. Biol."},{"key":"1548_CR199","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1016\/j.molcel.2025.09.031","volume":"85","author":"G Zhao","year":"2025","unstructured":"Zhao, G. et al. Engineered hypercompact Fanzor-\u03c9RNA system with enhanced genome editing activity. Mol. Cell 85, 4138\u20134151 (2025).","journal-title":"Mol. Cell"},{"key":"1548_CR200","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-74624-6","author":"S Chen","year":"2026","unstructured":"Chen, S. et al. Deep learning\u2013guided engineering of SpuFz1 and rational miniaturization of \u03c9RNA enables efficient genome editing. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-026-74624-6 (2026).","journal-title":"Nat. Commun."},{"key":"1548_CR201","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3390\/cells15020156","volume":"15","author":"C Bao","year":"2026","unstructured":"Bao, C. et al. Chronic in vivo CRISPR\u2013Cas genome editing: challenges, long-term safety, and outlook. Cells 15, 156 (2026).","journal-title":"Cells"},{"key":"1548_CR202","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37508-7","volume":"14","author":"N Yan","year":"2023","unstructured":"Yan, N. et al. Cytosine base editors induce off-target mutations and adverse phenotypic effects in transgenic mice. Nat. Commun. 14, 1784 (2023).","journal-title":"Nat. Commun."},{"key":"1548_CR203","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","volume":"52","author":"D Wilbie","year":"2019","unstructured":"Wilbie, D., Walther, J. & Mastrobattista, E. Delivery aspects of CRISPR\/Cas for in vivo genome editing. Acc. Chem. Res. 52, 1555\u20131564 (2019).","journal-title":"Acc. Chem. Res."},{"key":"1548_CR204","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac719","volume":"50","author":"J Hertler","year":"2022","unstructured":"Hertler, J. et al. Synthesis of point-modified mRNA. Nucleic Acids Res. 50, e115 (2022).","journal-title":"Nucleic Acids Res."},{"key":"1548_CR205","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","volume":"39","author":"SS Rosa","year":"2021","unstructured":"Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M. & Marques, M. P. C. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine 39, 2190\u20132200 (2021).","journal-title":"Vaccine"},{"key":"1548_CR206","doi-asserted-by":"crossref","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"L Schoenmaker","year":"2021","unstructured":"Schoenmaker, L. et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int. J. Pharm. 601, 120586 (2021).","journal-title":"Int. J. Pharm."},{"key":"1548_CR207","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/crispr.2024.0036","volume":"7","author":"CA George","year":"2024","unstructured":"George, C. A. et al. Genome editing therapy for the blood: ex vivo success and in vivo prospects. CRISPR J. 7, 231\u2013248 (2024).","journal-title":"CRISPR J."},{"key":"1548_CR208","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/vaccines9010065","volume":"9","author":"MD Buschmann","year":"2021","unstructured":"Buschmann, M. D. et al. Nanomaterial delivery systems for mRNA. Vaccines 9, 65 (2021).","journal-title":"Vaccines"},{"key":"1548_CR209","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s41573-023-00762-x","volume":"22","author":"V Madigan","year":"2023","unstructured":"Madigan, V., Zhang, F. & Dahlman, J. E. Drug delivery systems for CRISPR-based genome editors. Nat. Rev. Drug Discov. 22, 875\u2013894 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1548_CR210","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41578-022-00529-7","volume":"8","author":"SA Dilliard","year":"2023","unstructured":"Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282\u2013300 (2023).","journal-title":"Nat. Rev. Mater."},{"key":"1548_CR211","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41586-020-03086-7","volume":"589","author":"LW Koblan","year":"2021","unstructured":"Koblan, L. W. et al. In vivo base editing rescues Hutchinson\u2013Gilford progeria syndrome in mice. Nature 589, 608\u2013614 (2021).","journal-title":"Nature"},{"key":"1548_CR212","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.cell.2023.02.027","volume":"186","author":"GE McAuley","year":"2023","unstructured":"McAuley, G. E. et al. Human T cell generation is restored in CD3\u03b4 severe combined immunodeficiency through adenine base editing. Cell 186, 1398\u20131416 (2023).","journal-title":"Cell"},{"key":"1548_CR213","doi-asserted-by":"crossref","first-page":"eadj6779","DOI":"10.1126\/scitranslmed.adj6779","volume":"16","author":"V Bzhilyanskaya","year":"2024","unstructured":"Bzhilyanskaya, V. et al. High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease. Sci. Transl. Med. 16, eadj6779 (2024).","journal-title":"Sci. Transl. Med."},{"key":"1548_CR214","unstructured":"Research, C. for B. E. and. Safety assessment of genome editing in human gene therapy products using next-generation sequencing. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/safety-assessment-genome-editing-human-gene-therapy-products-using-next-generation-sequencing (2026)."},{"key":"1548_CR215","unstructured":"Center for Biologics Evaluation and Research. Human gene therapy products incorporating human genome editing. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-products-incorporating-human-genome-editing (2024)."},{"key":"1548_CR216","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2022016204","volume":"141","author":"W Qasim","year":"2023","unstructured":"Qasim, W. Genome-edited allogeneic donor \u201cuniversal\u201d chimeric antigen receptor T cells. Blood 141, 835\u2013845 (2023).","journal-title":"Blood"},{"key":"1548_CR217","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41587-022-01377-0","volume":"40","author":"AD Nahmad","year":"2022","unstructured":"Nahmad, A. D. et al. Frequent aneuploidy in primary human T cells after CRISPR\u2013Cas9 cleavage. Nat. Biotechnol. 40, 1807\u20131813 (2022).","journal-title":"Nat. Biotechnol."},{"key":"1548_CR218","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.molcel.2017.08.008","volume":"67","author":"P Billon","year":"2017","unstructured":"Billon, P. et al. CRISPR-mediated base editing enables efficient disruption of eukaryotic genes through induction of STOP codons. Mol. Cell 67, 1068\u20131079 (2017).","journal-title":"Mol. Cell"},{"key":"1548_CR219","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nmeth.4327","volume":"14","author":"C Kuscu","year":"2017","unstructured":"Kuscu, C. et al. CRISPR-STOP: gene silencing through base-editing-induced nonsense mutations. Nat. Methods 14, 710\u2013712 (2017).","journal-title":"Nat. Methods"},{"key":"1548_CR220","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22009-2","volume":"12","author":"MG Kluesner","year":"2021","unstructured":"Kluesner, M. G. et al. CRISPR\u2013Cas9 cytidine and adenosine base editing of splice-sites mediates highly-efficient disruption of proteins in primary and immortalized cells. Nat. Commun. 12, 2437 (2021).","journal-title":"Nat. Commun."},{"key":"1548_CR221","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1056\/NEJMoa2505478","volume":"394","author":"R Chiesa","year":"2026","unstructured":"Chiesa, R. et al. Universal base-edited CAR7 T cells for T-cell acute lymphoblastic leukemia. N. Engl. J. Med. 394, 152\u2013165 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1548_CR222","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","volume":"140","author":"C Diorio","year":"2022","unstructured":"Diorio, C. et al. Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL. Blood 140, 619\u2013629 (2022).","journal-title":"Blood"},{"key":"1548_CR223","first-page":"A69","volume":"8","author":"J Gehrke","year":"2020","unstructured":"Gehrke, J. et al. Highly efficient multiplexed base editing enables development of universal CD7-targeting CAR-T cells to treat T-ALL. J. Immunother. Cancer 8, A69 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1548_CR224","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1182\/blood-2019-130562","volume":"134","author":"JM Gehrke","year":"2019","unstructured":"Gehrke, J. M. et al. Highly efficient multiplexed base editing with minimized off-targets for the development of universal CAR-T cells to treat pediatric T-ALL. Blood 134, 5127 (2019).","journal-title":"Blood"},{"key":"1548_CR225","unstructured":"A Phase 1\/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed\/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) https:\/\/clinicaltrials.gov\/study\/NCT05885464 (Beam Therapeutics, 2025)."},{"key":"1548_CR226","doi-asserted-by":"crossref","first-page":"eaei0875","DOI":"10.1126\/scitranslmed.aei0875","volume":"18","author":"C Georgiadis","year":"2026","unstructured":"Georgiadis, C. et al. A phase 1 feasibility trial of BE-CAR33, an \u201coff-the-shelf\u201d base-edited CAR33 T cell therapy for acute myeloid leukemia. Sci. Transl. Med. 18, eaei0875 (2026).","journal-title":"Sci. Transl. Med."},{"key":"1548_CR227","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato, G. J. et al. Sickle cell disease. Nat. Rev. Dis. Primers 4, 18010 (2018).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1548_CR228","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","volume":"390","author":"RE Ware","year":"2017","unstructured":"Ware, R. E., Montalembert, M., de, Tshilolo, L. & Abboud, M. R. Sickle cell disease. Lancet 390, 311\u2013323 (2017).","journal-title":"Lancet"},{"key":"1548_CR229","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1126\/science.1165409","volume":"322","author":"VG Sankaran","year":"2008","unstructured":"Sankaran, V. G. et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322, 1839\u20131842 (2008).","journal-title":"Science"},{"key":"1548_CR230","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","volume":"330","author":"OS Platt","year":"1994","unstructured":"Platt, O. S. et al. Mortality in sickle cell disease \u2013 life expectancy and risk factors for early death. N. Engl. J. Med. 330, 1639\u20131644 (1994).","journal-title":"N. Engl. J. Med."},{"key":"1548_CR231","first-page":"PS2332","volume":"10","author":"PS Chockalingam","year":"2026","unstructured":"Chockalingam, P. S. et al. Ristoglogene autogetemcel treatment restored red blood cell health and function in patients with sickle cell disease, with sickling and rheology parameters comparable to sickle cell trait. HemaSphere 10, PS2332 (2026).","journal-title":"HemaSphere"},{"key":"1548_CR232","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-141805","volume":"136","author":"SH Chu","year":"2020","unstructured":"Chu, S. H. et al. Adenine base editing of the sickle allele in CD34+ hematopoietic stem and progenitor cells eliminates hemoglobin S. Blood 136, 47 (2020).","journal-title":"Blood"},{"key":"1548_CR233","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul, H. et al. Exagamglogene autotemcel for severe sickle cell disease. N. Engl. J. Med. 390, 1649\u20131662 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1548_CR234","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli, F. et al. Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia. N. Engl. J. Med. 390, 1663\u20131676 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1548_CR235","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-141498","volume":"136","author":"T Mayuranathan","year":"2020","unstructured":"Mayuranathan, T. et al. Adenosine base editing of \u03b3-globin promoters induces fetal hemoglobin and inhibit erythroid sickling. Blood 136, 21\u201322 (2020).","journal-title":"Blood"},{"key":"1548_CR236","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41586-026-10342-9","volume":"653","author":"Y Lai","year":"2026","unstructured":"Lai, Y. et al. Clinical application of base editing for treating \u03b2-thalassaemia. Nature 653, 923\u2013932 (2026).","journal-title":"Nature"},{"key":"1548_CR237","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.stem.2023.10.007","volume":"30","author":"W Han","year":"2023","unstructured":"Han, W. et al. Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs. Cell Stem Cell 30, 1624\u20131639 (2023).","journal-title":"Cell Stem Cell"},{"key":"1548_CR238","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.amjmed.2007.07.025","volume":"121","author":"T K\u00f6hnlein","year":"2008","unstructured":"K\u00f6hnlein, T. & Welte, T. Alpha-1 antitrypsin deficiency: pathogenesis, clinical presentation, diagnosis, and treatment. Am. J. Med. 121, 3\u20139 (2008).","journal-title":"Am. J. Med."},{"key":"1548_CR239","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/17476348.2023.2174973","volume":"17","author":"OF McElvaney","year":"2023","unstructured":"McElvaney, O. F., Fraughen, D. D., McElvaney, O. J., Carroll, T. P. & McElvaney, N. G. Alpha-1 antitrypsin deficiency: current therapy and emerging targets. Expert. Rev. Respir. Med. 17, 191\u2013202 (2023).","journal-title":"Expert. Rev. Respir. Med."},{"key":"1548_CR240","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1007\/s12325-026-03496-5","volume":"43","author":"R Mawani","year":"2026","unstructured":"Mawani, R., Pye, A. & Turner, A. M. Alpha-1 antitrypsin deficiency: current landscape of detection, management, and treatment. Adv. Ther. 43, 1408\u20131422 (2026).","journal-title":"Adv. Ther."},{"key":"1548_CR241","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.ymthe.2021.06.021","volume":"29","author":"RB Werder","year":"2021","unstructured":"Werder, R. B. et al. Adenine base editing reduces misfolded protein accumulation and toxicity in alpha-1 antitrypsin deficient patient iPSC-hepatocytes. Mol. Ther. 29, 3219\u20133229 (2021).","journal-title":"Mol. Ther."},{"key":"1548_CR242","unstructured":"Beam Therapeutics announces compelling updated clinical data from the ongoing phase 1\/2 Trial of BEAM-302 in alpha-1 antitrypsin deficiency (AATD) to support advancement to pivotal development. Beam Therapeutics https:\/\/investors.beamtx.com\/news-releases\/news-release-details\/beam-therapeutics-announces-compelling-updated-clinical-data\/ (2026)."},{"key":"1548_CR243","unstructured":"A phase 1\/2 dose-exploration and dose-expansion study to evaluate the safety and efficacy of BEAM-302 in adult patients with alpha-1 antitrypsin deficiency (AATD)-associated lung disease and\/or liver disease. Beam Therapeutics https:\/\/clinicaltrials.gov\/study\/NCT06389877 (2026)."},{"key":"1548_CR244","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI114578","volume":"85","author":"RG Crystal","year":"1990","unstructured":"Crystal, R. G. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J. Clin. Invest. 85, 1343\u20131352 (1990).","journal-title":"J. Clin. Invest."},{"key":"1548_CR245","unstructured":"YolTech Therapeutics announces positive interim data on YOLT-202 for the treatment of alpha-1 antitrypsin deficiency. YolTech https:\/\/www.yoltx.com\/news\/press-release\/107 (2026)."},{"key":"1548_CR246","unstructured":"YolTech Therapeutics receives FDA clearance to initiate phase 2\/3 study of in vivo gene-editing therapy YOLT-202 in alpha-1 antitrypsin deficiency (AATD). YolTech https:\/\/www.yoltx.com\/news\/press-release\/110 (2026)."},{"key":"1548_CR247","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen, J. C., Boerwinkle, E., Mosley, T. H. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264\u20131272 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1548_CR248","doi-asserted-by":"crossref","first-page":"100649","DOI":"10.1016\/j.ajpc.2024.100649","volume":"18","author":"O Mhaimeed","year":"2024","unstructured":"Mhaimeed, O. et al. The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: lower for longer is better. Am. J. Prev. Cardiol. 18, 100649 (2024).","journal-title":"Am. J. Prev. Cardiol."},{"key":"1548_CR249","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jacc.2026.02.5092","volume":"88","author":"AV Ambardekar","year":"2026","unstructured":"Ambardekar, A. V. et al. Gene editing therapy in cardiovascular disease: 2026 ACC Scientific Statement. J. Am. Coll. Cardiol. 88, 1157\u20131173 (2026).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1548_CR250","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/13543784.2024.2369747","volume":"33","author":"AJ Hooper","year":"2024","unstructured":"Hooper, A. J., Tang, X. L. & Burnett, J. R. VERVE-101, a CRISPR base-editing therapy designed to permanently inactivate hepatic PCSK9 and reduce LDL-cholesterol. Expert Opin. Investig. Drugs 33, 753\u2013756 (2024).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1548_CR251","unstructured":"Verve Therapeutics. Verve Therapeutics announces positive initial data from the Heart-2 phase 1b clinical trial of VERVE-102, an in vivo base editing medicine targeting PCSK9. GlobeNewswire News Room https:\/\/www.globenewswire.com\/news-release\/2025\/04\/14\/3060774\/0\/en\/Verve-Therapeutics-Announces-Positive-Initial-Data-from-the-Heart-2-Phase-1b-Clinical-Trial-of-VERVE-102-an-In-Vivo-Base-Editing-Medicine-Targeting-PCSK9.html (2025)."},{"key":"1548_CR252","unstructured":"Kolata, G. Baby is healed with world\u2019s first personalized gene-editing treatment. The New York Times https:\/\/www.nytimes.com\/2025\/05\/15\/health\/gene-editing-personalized-rare-disorders.html (2025)."},{"key":"1548_CR253","unstructured":"World\u2019s first patient treated with personalized CRISPR gene editing therapy at Children\u2019s Hospital of Philadelphia. Children\u2019s Hospital of Philadelphia https:\/\/www.chop.edu\/news\/worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital (2025)."},{"key":"1548_CR254","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/14728222.2017.1294685","volume":"21","author":"C Diez-Fernandez","year":"2017","unstructured":"Diez-Fernandez, C. & H\u00e4berle, J. Targeting CPS1 in the treatment of carbamoyl phosphate synthetase 1 (CPS1) deficiency, a urea cycle disorder. Expert Opin. Ther. Targets 21, 391\u2013399 (2017).","journal-title":"Expert Opin. Ther. Targets"},{"key":"1548_CR255","unstructured":"Research, C. for B. E. and. Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/studying-multiple-versions-cellular-or-gene-therapy-product-early-phase-clinical-trial (2022)."},{"key":"1548_CR256","unstructured":"Beam Therapeutics announces clearance of investigational new drug application for BEAM-304 for the treatment of phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration. Beam Therapeutics https:\/\/investors.beamtx.com\/news-releases\/news-release-details\/beam-therapeutics-announces-clearance-investigational-new-drug-0\/ (2026)."},{"key":"1548_CR257","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMsb2512695","volume":"393","author":"V Prasad","year":"2025","unstructured":"Prasad, V. & Makary, M. A. FDA\u2019s new plausible mechanism pathway. N. Engl. J. Med. 393, 2365\u20132367 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1548_CR258","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ajhg.2026.03.018","volume":"113","author":"ER Feierman","year":"2026","unstructured":"Feierman, E. R. et al. Implications of the FDA\u2019s new plausible mechanism framework for the development of a personalized in vivo prime editing platform. Am. J. Hum. Genet. 113, 891\u2013899 (2026).","journal-title":"Am. J. Hum. Genet."},{"key":"1548_CR259","unstructured":"Research, C. for B. E. and. Considerations for the use of the plausible mechanism framework to develop individualized therapies that target specific genetic conditions with known biological cause. FDA https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific (2026)."},{"key":"1548_CR260","unstructured":"Mast, J. & DeAngelis, A. Startup promising to scale custom CRISPR therapies abruptly scraps plans. STAT https:\/\/www.statnews.com\/2026\/08\/04\/aurora-therapeutics-ends-program-baby-kj-treatments-beam-therapeutics-jennifer-doudna\/ (2026)."},{"key":"1548_CR261","unstructured":"Exclusive: Death of girl in Chinese gene-editing trial was never made public. Science https:\/\/www.science.org\/content\/article\/exclusive-death-girl-chinese-gene-editing-trial-was-never-made-public (2026)."},{"key":"1548_CR262","unstructured":"Mast, J. & Yang, B. Once again, child dies in gene-editing trial in China, rekindling debate on transparency and safety. STAT https:\/\/www.statnews.com\/2026\/08\/05\/china-clinical-trial-fatality-safety-questions-investigator-led-studies\/ (2026)."},{"key":"1548_CR263","unstructured":"Mast, J. Vertex\u2019s CRISPR treatment for sickle cell disease hits unexpected roadblock. STAT https:\/\/www.statnews.com\/2026\/02\/05\/vertex-crispr-sickle-cell-treatment-casgevy-faces-rollout-bottleneck\/ (2026)."},{"key":"1548_CR264","unstructured":"CRISPR therapeutics provides business update and reports third quarter 2025 financial results. CRISPR Therapeutics https:\/\/ir.crisprtx.com\/news-releases\/news-release-details\/crispr-therapeutics-provides-business-update-and-reports-third-6\/ (2025)."},{"key":"1548_CR265","unstructured":"CASGEVYTM (gene editing). TIF https:\/\/thalassaemia.org.cy\/clinical-trial-updates\/exa-cel-gene-editing-thal\/ (2026)."},{"key":"1548_CR266","unstructured":"CRISPR therapeutics provides business update and reports fourth quarter and full year 2025 financial results. CRISPR Therapeutics https:\/\/ir.crisprtx.com\/news-releases\/news-release-details\/crispr-therapeutics-provides-business-update-and-reports-14\/ (2025)."},{"key":"1548_CR267","doi-asserted-by":"crossref","first-page":"bbac514","DOI":"10.1093\/bib\/bbac514","volume":"24","author":"K Han","year":"2023","unstructured":"Han, K. et al. A review of methods for predicting DNA N6-methyladenine sites. Brief. Bioinform. 24, bbac514 (2023).","journal-title":"Brief. Bioinform."},{"key":"1548_CR268","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40291-020-00445-y","volume":"24","author":"WH Peranteau","year":"2020","unstructured":"Peranteau, W. H. & Flake, A. W. The future of in utero gene therapy. Mol. Diagn. Ther. 24, 135\u2013142 (2020).","journal-title":"Mol. Diagn. Ther."},{"key":"1548_CR269","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s41591-018-0184-6","volume":"24","author":"AC Rossidis","year":"2018","unstructured":"Rossidis, A. C. et al. In utero CRISPR-mediated therapeutic editing of metabolic genes. Nat. Med. 24, 1513\u20131518 (2018).","journal-title":"Nat. Med."},{"key":"1548_CR270","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.siny.2017.05.003","volume":"22","author":"R Witt","year":"2017","unstructured":"Witt, R., MacKenzie, T. C. & Peranteau, W. H. Fetal stem cell and gene therapy. Semin. Fetal Neonatal Med. 22, 410\u2013414 (2017).","journal-title":"Semin. Fetal Neonatal Med."},{"key":"1548_CR271","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s40778-018-0117-9","volume":"4","author":"HA Hartman","year":"2018","unstructured":"Hartman, H. A., Rossidis, A. C. & Peranteau, W. H. In utero gene therapy and genome editing. Curr. Stem Cell Rep. 4, 52\u201360 (2018).","journal-title":"Curr. Stem Cell Rep."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01548-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01548-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01548-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:58:28Z","timestamp":1792173508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41573-026-01548-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":271,"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1038\/s41573-026-01548-7","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"8 September 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C.K. is an equity holder for Pairwise Plants and Beam Therapeutics, and receives royalties from Pairwise Plants, Beam Therapeutics and Editas Medicine via patents licensed from Harvard University. A.C.K.\u2019s interests have been reviewed and approved by the University of California San Diego in accordance with its conflict of interest policies. N.M.G. is an equity holder of Beam Therapeutics.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}